ESR1 and breast cancer: In our previous study [39], a relatively small number of samples were used for FCM analysis, and compared to those of the general breast cancer cohort, the clinicopathological characteristics of tumors were biased with larger invasive tumor sizes, more ER-negative cases, and higher Ki67 cases.